TAK-875– synthetic, GPR- 40 agonist

 

TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.                                                                                                      (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/21752941

 

Takeda moves potential first-in-class diabetes drug into phase III                      (news – 2011)

http://www.pharmafile.com/news/166980/takeda-diabetes-tak-875-phase-iii

 

A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes.       (abst – 2012)                                  http://www.ncbi.nlm.nih.gov/pubmed/22669289

 

Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.                                                                                                   (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22490067

 

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial.                                                                             (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22374408

Share a link for